OBJECTIVES : The British Association of Dermatologists Biologics and Immunomodulator Register (BADBIR) is prospectively recording real world outcomes for patients with psoriasis in the UK and Republic of Ireland receiving biologic and non-biologic immunomodulatory treatments, including the anti-IL-17A monoclonal antibody ixekizumab. Objectives of this study were to describe baseline patient characteristics, continuation with ixekizumab and disease activity at the first post-baseline follow-up.

METHODS : The BADBIR ixekizumab cohort included patients initiating treatment with ixekizumab in the previous six months for their psoriasis. The analysis population was restricted to those aged 18 years or older using ixekizumab at the dose permitted for psoriasis in the EU label. Data was included for the period May 2017 to September 2019. Descriptive analyses of ixekizumab continuation and PASI at follow-up were restricted to those with at least one follow-up visit recorded (for PASI, record of a score within a window 6 months post initiation +/- 2 months was required).

RESULTS : During the study period 371 patients were enrolled to the BADBIR ixekizumab cohort. At baseline, mean PASI was 13.2 (sd 8), mean disease duration was 24.2 years (sd 12.5), 45.0% of patients were female, 83.5% were biologic-experienced and 27.2% were using ixekizumab with a conventional systemic immunosuppressant drug. 192 patients completed a follow-up visit of whom 166 (86.5%, 95% CI 80.8-91.0.) remained on ixekizumab. In 153 patients with a 6 month PASI score, mean PASI was 3.3 (sd 5.1); 69.5% and 42.2% had achieved PASI ≤3 and ≤1 respectively.

CONCLUSIONS : These data on ixekizumab from clinical practice in the UK and Ireland showing, in those completing next follow-up, >85% retention and lower PASI are supportive of results seen in the clinical trial program. Further analyses will enable more detailed assessment of outcomes with a larger sample size, at later follow-ups and with investigation of sub-groups.